Details of Disease

General Information of Disease (ID: DISQOYF5)

• Disease Name: Generalized myasthenia gravis
• Synonyms: torsion spasm, Progressive; torsion dystonia, Idiopathic; torsion dystonia; torsion disease, childhood; torsion disease of childhood; symptomatic torsion dystonia; spasm, Progressive torsion; idiopathic torsion dystonia; idiopathic non-familial dystonia; idiopathic familial dystonia; fragments of torsion dystonia; familial dystonia; dystonias, torsion; dystonias, Idiopathic torsion; dystonia, Idiopathic torsion; dystonia musculorum deformans; dystonia deformans musculorum; dystonia 12; childhood torsion disease; Progressive torsion spasm; Oppenheim-Ziehen disease; Oppenheim Ziehen disease; Idiopathic torsion dystonias; Idiopathic torsion dystonia; generalized isolated dystonia; generalised isolated dystonia; dystonia deformans progressiva
• Disease Class: 8C60: Myasthenia gravis
• Disease Hierarchy:
  DISH6KEJ: Isolated dystonia
  DISQOYF5: Generalized myasthenia gravis
• ICD Code: ICD-11: ICD-11: 8C60
• Disease Identifiers:
  MONDO ID: MONDO_0000476
  UMLS CUI: C1848954
  MedGen ID: 341342
  HPO ID: HP:0007325
  Orphanet ID: 376724
  SNOMED CT ID: 425492002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Rozanolixizumab	DMK0NGB	Approved	NA	[1]
Zilucoplan	DM9Z4N5	Approved	NA	[2]

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ALXN1720	DMOB3CI	Phase 3	Monoclonal antibody	[3]
Nipocalimab?	DM0DYAX	Phase 3	Monoclonal antibody	[4]
Vemircopan	DM3RZ9H	Phase 2	Small molecule	[5]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761286
• [2] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216834
• [3] ClinicalTrials.gov (NCT05556096) A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis. U.S.National Institutes of Health.
• [4] ClinicalTrials.gov (NCT05265273) An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis. U.S.National Institutes of Health.
• [5] ClinicalTrials.gov (NCT05218096) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis. U.S.National Institutes of Health.